A CfNN Focus Area: Research in Restoring Mental Health employs noninvasive neurotechnologies such as transcranial magnetic stimulation (TMS) and transcranial electrical stimulation (using direct or alternating current; tDCS or tACS, respectively) to understand and change abnormal brain circuit functioning in a group of neurobehavioral disorders that impose health and functional burdens on Veterans, including post-traumatic stress disorder (PTSD), depression, suicide, chronic pain, and obsessive-compulsive disorder (OCD). To map brain circuit function in these conditions we use advanced MRI and electroencephalography methods in collaboration with Neuroimaging and Recording, Decoding, and Computational Neuroscience, with implementation and deployment guided by Assessment, Outcome Measurement, and Implementation.

TMS positioning.

Some Mental Health Research Projects:

Research demonstrating that non-invasive brain stimulation, coupled with virtual reality or on its own, can improve PTSD: Research has demonstrated that tDCS, combined with virtual reality exposure, can improve PTSD (van ‘t Wout-Frank et al., 2019); these results led to a Merit-funded study (I01 RX002450) to test this intervention more broadly. FA-2 also conducted the first randomized controlled study of a novel TMS paradigm (intermittent theta burst) in Veterans with PTSD (Philip et al., 2019). Recent awards of VA equipment grants (IS1 BX004779) will permit the first-in-human testing of low intensity focused ultrasound for depression, anxiety and PTSD.

Therapeutic TMS suggests that the antidepressant response to TMS can be predicted by specific patterns in brain connectivity before treatment for depression: Ongoing work on therapeutic TMS suggests that the antidepressant response to TMS can be predicted by specific patterns in brain connectivity before treatment (Philip et al., 2018; further funded by I01 RX003152). Furthermore, FA-2 research demonstrated that data-driven, machine learning approaches can identify patients most likely to respond to TMS (Zandvakili et al., 2019), and help clinicians determine which patients are most suitable for TMS (Berlow et al., 2019).

Identification of neural circuits underlying risk of suicide: Investigators have identified neural circuits underlying suicide in PTSD (Barredo et al, 2018), and ongoing work is identifying how neuroimaging can identify those at risk for suicide (IK2 CX001824). In collaboration with local health services researchers, we launched the first study to combine brain stimulation and psychotherapy to reduce suicide in high-risk Veterans (I01 HX002572).

Research evaluating the emotional (affective) component of chronic pain: Research evaluating the emotional (affective) component of chronic pain, a clinical feature which magnifies pain-related disability; FA-2 research demonstrated that tDCS can improve pain tolerance (Mariano et al., 2015) and demonstrate improvements in pain-related interference and disability—as well as depression–relative to a placebo condition in a double-blinded RCT (Mariano et al. 2019). Other FA-2 research focused on the use of tACS to modulate pain-related somatosensory perception (Sliva et al., 2018).

Investigations of Deep Brain Stimulation for individuals suffering with intractable illness and the use of tDCS to modulate brain regions implicated in OCD: Investigators completed 12-month data collection in a multicenter NIH-supported trial of deep brain stimulation for individuals suffering with intractable illness (Greenberg, PI) and are contributing the data analyses. Ongoing work also indicates the use of tDCS to modulate brain regions implicated in OCD.

Therapeutic transcranial magnetic stimulation is efficacious for PTSD. Work from FA2 and colleagues around VA have reported that therapeutic transcranial magnetic stimulation (TMS) can reduce symptoms of PTSD; in fact,  after stimulation 65.3% demonstrated a clinically meaningful reduction in PTSD symptoms, and 46.1% no longer met PTSD criteria (Madore et al., 2022). Furthermore, the team has demonstrated that Veterans with mild traumatic brain injury also respond well to therapeutic TMS at rates that are comparable to those without traumatic brain injuries (Philip et al., 2023).

Profile picture of Noah Philip
Focus Area Lead

Noah Philip, MD

Default Profile picture

Hannah Adams, BS

Profile picture of Jennifer Barredo
Core Lead

Jennifer Barredo, PhD

Profile picture of Yosef Berlow

Yosef Berlow, MD, PhD

Profile picture of Melanie Bozzay

Melanie Bozzay, PhD

Profile picture of Erica Eaton

Erica Eaton, PhD

Profile picture of Mascha (van ’t Wout) Frank

Mascha (van ’t Wout) Frank, PhD

Profile picture of Benjamin D. Greenberg
Associate Director

Ben Greenberg, MD, PhD

Profile picture of Timothy Mariano

Timothy Mariano, MD, PhD, MSc

Default Profile picture

John McGeary, PhD

Default Profile picture

M. Tracie Shea, PhD

Default Profile picture

Robert Swift, MD, PhD

Profile picture of Ryan Van Patten, PhD, ABPP

Ryan Van Patten, PhD, ABPP

Profile picture of Amin Zand Vakili

Amin Zand Vakili, MD, PhD